Brain chemical may unlock migraine mystery
NCT ID NCT07451769
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study gives a natural brain chemical called adrenomedullin to 26 people with migraines to see if it triggers an attack. Participants first receive a migraine-preventing drug (erenumab) to block related receptors. The goal is to understand how migraines start, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adrenomedullin
- What this could lead to
- If it works, this could help explain how migraines start and point to new treatment targets.
- What could go wrong
- This is a very small, early-stage study (26 people) that only looks at migraine triggers, not a treatment. It may not apply to everyone with migraines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOMEDULLIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Danish Headache Center
Glostrup Municipality, 2600, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tape to tame Post-Surgery face swelling?
- Electric pulses on the wrist may tame colonoscopy pain
- Virtual reality may distract patients from pain and fear during anesthesia
- Can a numbing nose treatment stop migraine pain in its tracks?
- Could a gentle yoga practice turn down the Body's pain and inflammation?
- Can a 5-Pill opioid prescription match a 30-Pill one after hip surgery?